Machina Capital S.A.S. Has $849,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Machina Capital S.A.S. reduced its position in Pfizer Inc. (NYSE:PFE) by 70.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 32,016 shares of the biopharmaceutical company’s stock after selling 74,740 shares during the period. Machina Capital S.A.S.’s holdings in Pfizer were worth $849,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Washington Trust Advisors Inc. lifted its stake in Pfizer by 0.7% in the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock valued at $1,424,000 after purchasing an additional 360 shares during the last quarter. PSI Advisors LLC lifted its stake in Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 385 shares during the last quarter. Waddell & Associates LLC lifted its stake in Pfizer by 1.6% in the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after purchasing an additional 388 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after purchasing an additional 391 shares during the last quarter. Finally, D Orazio & Associates Inc. lifted its stake in Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 391 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on PFE shares. Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Guggenheim restated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. Finally, UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $26.71 on Friday. The company’s 50 day simple moving average is $26.30 and its 200 day simple moving average is $27.24. The stock has a market capitalization of $151.35 billion, a price-to-earnings ratio of 18.94, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.44%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.